# Deciphering the disease ecosystem of ischemic stroke via multi-omics and prospects for therapeutic strategies

**Authors:** Jingwen Zhang, Jiajie Niu, Jingwen Zhao, Linjing Wang, Tuozi Wang, Shuai Shi

PMC · DOI: 10.3389/fnins.2026.1740084 · Frontiers in Neuroscience · 2026-02-17

## TL;DR

This paper redefines ischemic stroke as a complex 'disease ecosystem' and proposes new therapeutic strategies targeting the whole system rather than single components.

## Contribution

Introduces the concept of 'ecosystem engineering' as a novel therapeutic framework for ischemic stroke.

## Key findings

- Ischemic stroke involves five interconnected features like cellular collapse and immune miscommunication.
- Current single-target therapies fail due to the complex, dynamic nature of the disease ecosystem.
- Proposes temporally adaptive and network-coordinated interventions for precision neural repair.

## Abstract

Ischemic stroke (IS) remains a leading cause of disability due to the translational failure of single-target therapies, underscoring the limitations of the traditional neuron-centric view. This review proposes a paradigm shift by conceptualizing IS as a dynamically evolving “disease ecosystem.” We integrate multi-omics evidence to delineate five interconnected core features—cellular identity collapse, inflammatory-reparative imbalance, neurovascular unit disintegration, brain-peripheral immune miscommunication, and extracellular matrix scarring—that form a pathological logic axis driving disease progression. Based on this systemic understanding, we advance the novel therapeutic strategy of “ecosystem engineering,” which emphasizes temporally adaptive, spatially precise, and network-coordinated interventions. This framework aims to overcome current therapeutic bottlenecks and usher in a new era of precision neural repair.

Decoding the ischemic stroke disease ecosystem: from systemic collapse to therapeutic remodeling. The graphical abstract conceptualizes the paradigm shift from a traditional neuron-centric view to a holistic “disease ecosystem” perspective in ischemic stroke. The left panel (Ecosystem Homeostasis) symbolizes the balanced multicellular community in a healthy brain. The central panel (Cascade Collapse) depicts the five interconnected core features (cellular identity collapse, inflammation-repair imbalance, NVU disintegration, brain-peripheral immune miscommunication, and ECM scarring) that drive ecosystem failure following ischemia. The right panel (Therapeutic Ecosystem Engineering) illustrates the proposed intervention strategy, guided by three core principles: temporally dynamic, spatially precise, and network-coordinated interventions, aimed at steering the damaged ecosystem from a pathological state toward functional recovery. “Graphical Abstract” created in BioRender. Hong, Zhi (https://BioRender.com/hj9yl80) is licensed under CC BY 4.0.Corresponding license: Publication License Jan-13-2026.pdf (Agreement number: JI298E4MNO).
Infographic contrasting single-target approaches and ecosystem-based strategies for ischemic stroke. It illustrates failures of neuron-centric views, highlights issues like cellular collapse, inflammatory imbalance, immune miscommunication, NVU disintegration, ECM scarring, and advocates for coordinated temporal and spatial intervention strategies to rebalance the disease ecosystem.

Decoding the ischemic stroke disease ecosystem: from systemic collapse to therapeutic remodeling. The graphical abstract conceptualizes the paradigm shift from a traditional neuron-centric view to a holistic “disease ecosystem” perspective in ischemic stroke. The left panel (Ecosystem Homeostasis) symbolizes the balanced multicellular community in a healthy brain. The central panel (Cascade Collapse) depicts the five interconnected core features (cellular identity collapse, inflammation-repair imbalance, NVU disintegration, brain-peripheral immune miscommunication, and ECM scarring) that drive ecosystem failure following ischemia. The right panel (Therapeutic Ecosystem Engineering) illustrates the proposed intervention strategy, guided by three core principles: temporally dynamic, spatially precise, and network-coordinated interventions, aimed at steering the damaged ecosystem from a pathological state toward functional recovery. “Graphical Abstract” created in BioRender. Hong, Zhi (https://BioRender.com/hj9yl80) is licensed under CC BY 4.0.Corresponding license: Publication License Jan-13-2026.pdf (Agreement number: JI298E4MNO).

## Linked entities

- **Diseases:** ischemic stroke (MONDO:1060198)

## Full-text entities

- **Genes:** Rhoa (ras homolog family member A) [NCBI Gene 11848] {aka Arha, Arha1, Arha2}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156] {aka CD140A, PDGFR-2, PDGFR2}, CSPG4 (chondroitin sulfate proteoglycan 4) [NCBI Gene 1464] {aka CSPG4A, HMW-MAA, MCSP, MCSPG, MEL-CSPG, MSK16}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, Lar (low antibody response) [NCBI Gene 104121], EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, RHO (rhodopsin) [NCBI Gene 6010] {aka CSNBAD1, OPN2, RP4}, RTN4R (reticulon 4 receptor) [NCBI Gene 65078] {aka NGR, NOGOR, NgR1}, PDGFB (platelet derived growth factor subunit B) [NCBI Gene 5155] {aka IBGC5, PDGF-2, PDGF2, SIS, SSV, c-sis}, Syn1 (synapsin I) [NCBI Gene 20964] {aka Syn-1, Syn1-S}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, AQP4 (aquaporin 4) [NCBI Gene 361] {aka MIWC, MLC4, WCH4, hAQP4}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, NTF3 (neurotrophin 3) [NCBI Gene 4908] {aka HDNF, NGF-2, NGF2, NT-3, NT3}, PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, Vcan (versican) [NCBI Gene 13003] {aka 5430420N07Rik, 9430051N09, Cspg2, DPEAAE, PG-M, PG-M(V0)}, Map2 (microtubule-associated protein 2) [NCBI Gene 17756] {aka G1-397-34, MAP-2, Mtap-2, Mtap2, repro4}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CCR2 (C-C motif chemokine receptor 2) [NCBI Gene 729230] {aka CC-CKR-2, CCR-2, CCR2A, CCR2B, CD192, CKR2}, Rtn4r (reticulon 4 receptor) [NCBI Gene 65079] {aka NOGOR, NgR, NgR1}, ANGPT1 (angiopoietin 1) [NCBI Gene 284] {aka AGP1, AGPT, AGPT-1, ANG1, HAE5}, CLDN5 (claudin 5) [NCBI Gene 7122] {aka AWAL, BEC1, CPETRL1, TMDVCF, TMVCF}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, S100A9 (S100 calcium binding protein A9) [NCBI Gene 6280] {aka 60B8AG, CAGB, CFAG, CGLB, L1AG, LIAG}, Ptprs (protein tyrosine phosphatase receptor type S) [NCBI Gene 19280] {aka PTP, PTP-NU3, PTPNU-3, PTPsigma, Ptpt9, R-PTP-S}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, Acan (aggrecan) [NCBI Gene 11595] {aka Agc, Agc1, CSPCP, Cspg1, b2b183Clo, cmd}, TEK (TEK receptor tyrosine kinase) [NCBI Gene 7010] {aka CD202B, GLC3E, TIE-2, TIE2, VMCM, VMCM1}, Mbp (myelin basic protein) [NCBI Gene 17196] {aka Hmbpr, golli-mbp, jve, mld, shi}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, S100A10 (S100 calcium binding protein A10) [NCBI Gene 6281] {aka 42C, ANX2L, ANX2LG, CAL1L, CLP11, Ca[1]}, Bcan (brevican) [NCBI Gene 12032] {aka Cspg7}, DCX (doublecortin) [NCBI Gene 1641] {aka DBCN, DC, LISX, SCLH, XLIS}, Mmp2 (matrix metallopeptidase 2) [NCBI Gene 17390] {aka Clg4a, GelA, MMP-2}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, VIM (vimentin) [NCBI Gene 7431], IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CRYGC (crystallin gamma C) [NCBI Gene 1420] {aka CCL, CRYG3, CTRCT2}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, C4B (complement C4B (Chido/Rodgers blood group)) [NCBI Gene 721] {aka C4B1, C4B12, C4B3, C4B5, C4BD, C4F}, OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}, ALDH1L1 (aldehyde dehydrogenase 1 family member L1) [NCBI Gene 10840] {aka 10-FTHFDH, 10-fTHF, FDH, FTHFD}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, NEUROD1 (neuronal differentiation 1) [NCBI Gene 4760] {aka BETA2, BHF-1, MODY6, NEUROD, T2D, bHLHa3}
- **Diseases:** infectious complications (MESH:D003141), necrosis (MESH:D009336), post-stroke immune dysregulation (OMIM:614878), glutamate excitotoxicity (MESH:C537425), splenic atrophy (MESH:D013158), infarct (MESH:D007238), proinflammatory cytokines (MESH:D000080424), neuronal damage (MESH:D009410), cerebrovascular diseases (MESH:D002561), IS (MESH:D002544), Ischemic injury (MESH:D017202), NVU (MESH:D013901), infection (MESH:D007239), intracerebral injury (MESH:D002543), acute injury (MESH:D001930), reperfusion injury (MESH:D015427), hypoxia (MESH:D000860), neurological deficits (MESH:D009461), ischemia (MESH:D007511), SIID (MESH:D020521), EndMT (MESH:C535700), hemorrhagic (MESH:D006470), cerebral edema (MESH:D001929), neuroinflammation (MESH:D000090862), edema (MESH:D004487), BBB dysfunction (MESH:C536830), ischemic brain (MESH:D020520), Ischemic (MESH:D002545), lymphopenia (MESH:D008231), inflammation (MESH:D007249), pulmonary infections (MESH:D012141)
- **Chemicals:** ROS (MESH:D017382), short-chain fatty acid (MESH:D005232), glucose (MESH:D005947), Natalizumab (MESH:D000069442), minocycline (MESH:D008911), ATP (MESH:D000255), glycosaminoglycan (MESH:D006025), Enlimomab (MESH:C474712), NXY- (-), Tirilazad (MESH:C053355), oxygen (MESH:D010100)
- **Species:** gut metagenome (species) [taxon 749906], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953568/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12953568/full.md

## References

107 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953568/full.md

---
Source: https://tomesphere.com/paper/PMC12953568